KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) FCF Margin (2016 - 2026)

Neogenomics filings provide 17 years of FCF Margin readings, the most recent being 7.04% for Q1 2026.

  • On a quarterly basis, FCF Margin rose 1071.0% to 7.04% in Q1 2026 year-over-year; TTM through Mar 2026 was 2.71%, a 157.0% increase, with the full-year FY2025 number at 0.48%, down 43.0% from a year prior.
  • FCF Margin hit 7.04% in Q1 2026 for Neogenomics, down from 9.87% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 22.24% in Q4 2024 to a low of 31.8% in Q1 2022.
  • Median FCF Margin over the past 5 years was 0.93% (2024), compared with a mean of 3.87%.
  • The widest YoY moves for FCF Margin: up 4039bps in 2022, down -3191bps in 2022.
  • Neogenomics' FCF Margin stood at 15.13% in 2022, then dropped by -24bps to 11.45% in 2023, then surged by 94bps to 22.24% in 2024, then tumbled by -56bps to 9.87% in 2025, then tumbled by -171bps to 7.04% in 2026.
  • The last three reported values for FCF Margin were 7.04% (Q1 2026), 9.87% (Q4 2025), and 0.3% (Q3 2025) per Business Quant data.